#1 Clinical Trials Search in Europe

Tecovirimat

Tecovirimat, also known as TPOXX or ST-246, is an antiviral medication being studied in clinical trials for the treatment of orthopoxvirus infections, including smallpox and monkeypox. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of tecovirimat in various patient populations and dosing regimens. The research could lead to improved treatment options for these potentially serious viral infections.

Table of Contents

What is TECOVIRIMAT?

TECOVIRIMAT, also known by its brand name TPOXX or ST-246, is an antiviral medication designed to combat certain viral infections[1]. It’s a relatively new drug that has gained attention for its potential in treating serious viral diseases that previously had limited treatment options.

What Diseases Does TECOVIRIMAT Treat?

TECOVIRIMAT is primarily used to treat infections caused by orthopoxviruses, a family of viruses that includes several dangerous pathogens. Specifically, it’s approved or being studied for the following conditions:

  • Smallpox: TECOVIRIMAT is approved by the FDA for the treatment of smallpox, a highly contagious and potentially fatal disease that has been eradicated in the wild but remains a concern for bioterrorism[1].
  • Monkeypox (mpox): This viral infection, which causes flu-like symptoms and a distinctive rash, is another target for TECOVIRIMAT treatment[2].
  • Other orthopoxvirus infections: TECOVIRIMAT may be used to treat infections caused by related viruses, such as cowpox[3].
  • Adverse reactions to smallpox vaccine: In some cases, TECOVIRIMAT might be used to treat severe reactions to the smallpox vaccine[3].

How Does TECOVIRIMAT Work?

TECOVIRIMAT works by interfering with a protein that the virus needs to spread to other cells in the body. By blocking this protein, the medication helps to stop the virus from reproducing and spreading, allowing the immune system to fight off the infection more effectively[1].

How is TECOVIRIMAT Administered?

TECOVIRIMAT is typically given as an oral medication in the form of capsules. The dosage and duration of treatment can vary depending on the specific condition being treated and the patient’s characteristics:

  • For adults weighing 40 kg (88 pounds) or more, the usual dose is 600 mg (three 200 mg capsules) taken twice daily for 14 days[1].
  • For children and adults weighing less than 40 kg, the dose is adjusted based on body weight[1].
  • In some cases, TECOVIRIMAT may be given intravenously (through a vein) if a patient cannot take oral medication[3].

It’s important to take TECOVIRIMAT with food, as this helps the body absorb the medication more effectively[1].

TECOVIRIMAT in Clinical Trials

Several clinical trials are ongoing or have been completed to evaluate the safety and effectiveness of TECOVIRIMAT:

  • A study is assessing TECOVIRIMAT’s use in non-hospitalized patients with monkeypox, comparing it to a placebo[2].
  • Another trial is evaluating TECOVIRIMAT in adults and children with monkeypox in the Democratic Republic of Congo[4].
  • Researchers are also studying the use of TECOVIRIMAT in people weighing more than 120 kg (264 pounds) to determine if dosage adjustments are needed[5].

Potential Side Effects

Like all medications, TECOVIRIMAT can cause side effects. While not everyone experiences side effects, it’s important to be aware of potential issues. Common side effects may include:

  • Headache
  • Nausea
  • Abdominal pain
  • Vomiting

More serious side effects are rare but possible. Clinical trials are ongoing to better understand the safety profile of TECOVIRIMAT[2][4].

Special Considerations

There are a few important points to keep in mind regarding TECOVIRIMAT:

  • Pregnancy and breastfeeding: The safety of TECOVIRIMAT during pregnancy or while breastfeeding is not yet fully known. If you’re pregnant or breastfeeding, discuss the potential risks and benefits with your healthcare provider.
  • Drug interactions: TECOVIRIMAT may interact with other medications. Always inform your doctor about all medications and supplements you’re taking.
  • Monitoring: While taking TECOVIRIMAT, your doctor may want to monitor you closely, especially if you’re participating in a clinical trial[2][4].

TECOVIRIMAT represents an important advancement in the treatment of orthopoxvirus infections. As research continues, we may learn more about its potential uses and effectiveness. If you have any questions or concerns about TECOVIRIMAT, always consult with your healthcare provider for personalized advice.

Aspect Details
Drug Name Tecovirimat (TPOXX, ST-246)
Target Conditions Smallpox, Monkeypox, other Orthopoxvirus infections
Administration Oral capsules, typically 600 mg twice daily for 14 days
Main Study Outcomes Lesion healing time, viral clearance, symptom resolution, safety profile
Study Designs Randomized, placebo-controlled, double-blind trials; observational studies
Patient Populations Adults and some adolescents with confirmed/suspected infections; healthy volunteers for PK studies
Safety Considerations Monitoring for adverse events, laboratory tests, vital signs, ECG changes
Potential Benefits Faster lesion healing, reduced symptom duration, prevention of complications

FAQ

  • What is tecovirimat and what is it used for? Tecovirimat (TPOXX) is an antiviral medication approved for treating smallpox. It is being studied in clinical trials for treating other orthopoxvirus infections like monkeypox. It works by preventing the virus from spreading to other cells in the body.
  • How is tecovirimat administered in clinical trials? In most trials, tecovirimat is given as oral capsules. The typical adult dose is 600 mg (three 200 mg capsules) taken twice daily for 14 days. Dosing may be adjusted based on a patient's weight.
  • What are the main outcomes being studied in tecovirimat trials? Key outcomes include time to lesion healing, viral clearance, symptom resolution, safety/side effects, and for monkeypox specifically – time to scabbing/desquamation of skin lesions.
  • Who can participate in tecovirimat clinical trials? Eligibility varies, but trials are enrolling adults and some adolescents with confirmed or suspected orthopoxvirus infections like monkeypox. Some studies also include healthy volunteers to assess safety and pharmacokinetics.
  • Are there any known side effects of tecovirimat? Common side effects reported in trials include headache, nausea, and abdominal pain. However, the trials are still evaluating the full safety profile of tecovirimat when used to treat orthopoxvirus infections.

Ongoing Clinical Trials on Tecovirimat

  • Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Ireland Italy The Netherlands Norway +2

  • Study on Tecovirimat for Treating Monkeypox in Patients with Confirmed Infection

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Norway +2

Glossary

  • Orthopoxvirus: A genus of viruses that includes smallpox, monkeypox, cowpox, and vaccinia. These viruses can cause skin lesions and other symptoms in humans and animals.
  • Tecovirimat: An antiviral medication (also known as TPOXX or ST-246) that works by preventing orthopoxviruses from spreading to other cells in the body.
  • Monkeypox: A viral infection caused by the monkeypox virus, characterized by fever and a distinctive rash. It's related to smallpox but generally less severe.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect. It's used as a control in clinical trials to compare against the active treatment.
  • Standard of Care (SOC): The currently accepted treatment for a specific condition, used as a comparison in clinical trials of new treatments.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • PCR (Polymerase Chain Reaction): A laboratory technique used to detect the presence of viral genetic material, often used to confirm infections like monkeypox.
  • Lesion: An area of abnormal tissue change, such as the skin sores or rashes caused by orthopoxvirus infections.
  • Efficacy: The ability of a treatment to produce the desired result under ideal circumstances, such as in a controlled clinical trial.

References

  1. https://clinicaltrials.gov/study/NCT02080767
  2. https://clinicaltrials.gov/study/NCT05534165
  3. https://clinicaltrials.gov/study/NCT05380752
  4. https://clinicaltrials.gov/study/NCT05559099
  5. https://clinicaltrials.gov/study/NCT04392739